IFNA2 and type 1 diabetes mellitus: The autoantibodies commonly neutralized their targets in vivo, and APS1/APECED patients with signature type 1 diabetes (T1D)-associated antibodies (e.g., anti-GAD65) commonly failed to develop T1D so long as they harbored powerfully neutralizing IFNα-specific antibodies.